Abstract:
본 발명은 하기 화학식 1 표시되는, 아다만틸기를 갖는 설파마이드 유도체 또는 이의 약제학적으로 허용 가능한 염이 제공된다. 상기 설파마이드 유도체는 11베타 하이드록시스테로이드 디하이드로게나이제 유형1(11β-hydroxysteroid dehydrogenase type1, 11β-HSD1)의 활성을 억제하여, 11β-HSD1에 의해 매개되는 각종 질환을 치료하는데 유용하다.
Abstract:
본 발명은 하기 화학식 1 표시되는, 아다만틸기를 갖는 설파마이드 유도체 또는 이의 약제학적으로 허용 가능한 염이 제공된다. 상기 설파마이드 유도체는 11베타 하이드록시스테로이드 디하이드로게나아제 유형1(11 β -hydroxysteroid dehydrogenase type1, 11 β -HSD1)의 활성을 억제하여, 11 β -HSD1에 의해 매개되는 각종 질환을 치료하는데 유용하다.
Abstract:
본 발명은 이미다조 페닐테트라졸 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 골다공증, 비만, 당뇨 또는 고지혈증의 예방 또는 치료용 약학적 조성물에 관한 것으로서, 상기 유도체는 TAZ 단백질을 조절하므로, 골다공증, 비만, 당뇨 또는 고지혈증의 예방 또는 치료에 유용하게 사용될 수 있다. 이미다조 페닐테트라졸 유도체, TAZ, 골다공증, 비만, 당뇨, 고지혈증
Abstract:
하기 화학식 1로 표시되는, 베타아미노기를 갖는 1,2,5-트리아제판 유도체 또는 이의 약학적으로 허용 가능한 염이 제공된다. 이 1,2,5-트리아제판 유도체는 DPP-IV의 활성을 억제하여, DPP-IV에 의해 매개되는 각종 질환을 치료하는데 유용하다. [화학식 1]
상기 식에서, R 1 , R 2 및 R 3 은 명세서에 정의되는 바와 같다. 1,2,5-트리아제판 유도체, DPP-IV, 제조 방법, 약학 조성물
Abstract:
A 1,4-diazepane derivative is provided to inhibit the activity of DPP-IV excellently, thereby being effectively used to treat or prevent diseases such as insuline-dependent and insuline-independent diabetes, arthritis, obesity, osteoporosis and injured glucose resistance. A 1,4-diazepane derivative having a beta-amino group is represented by a formula(1), wherein R1 is a group(1) or a group(2); R2 is H, C1-6 alkyl, C3-6 cycloalkyl, C1-6 haloalkyl, heteroaryl, a group(1), a group(2), a group(3), a group(4), a group(5), a group(6), a group(7), a group(8), or a group(9); R2 is H, C1-6 alkyl, C3-6 cycloalkyl, heteroaryl, C1-6 alkoxy, -OCH2O, -SO2NH3, -OCF3, phenoxy, halogen, -CN, -NO2, -CF3, -CONH2, -COOR^b, -CH2COOR^b, -OCHR^bCOOR^b or -NR^bR^c; each R^b and R^c is independently H, C1-6 alkyl or C3-6 cycloalkyl, aryl, alkylaryl, arylsulfonyl, arylcarbonyl, amino acid derivative or -CH2OCOC(CH3)3; R^d is C1-6 alkyl, trifluoromethyl, a group(1), a group(2), a group(10), a group(11), a group(12), a group(13), pyrazinyl, pyrimidinyl or pyrrolyl; R^e is C1-6 alkyl, C3-6 cycloalkyl, a group(1) or a group(2); R^f is, halogen, NR^bR^c, a group(14), a group(15), a group(16), a group(17), a group(10), heteroaryl, -S-heteroaryl, tetrahydroisoquinoline, thiazolidine, piperidin-4-carboxylic acid or tetrahydropyrimidine; A is CH2, N, O or S; B is H, C1-6 alkyl, C3-6 cycloalkyl, benzyl, CO2R^d, 2-pyridyl or aryl; X is O or S; and n is an integer from 1 to 3. A method for preparing the 1,4-diazepane derivative comprises the steps of: (a) subjecting an amino acid represented by a formula(2) and a diazepane compound represented by a formula(3) to condensation to obtain a compound represented by a formula(4); and (b) deprotecting the compound of the formula(4), wherein BOC is a protecting group, and other substitutents are same as defined above. A pharmaceutical composition comprises an effective amount of the 1,4-diazepane derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Abstract translation:提供1,4-二氮杂环庚烷衍生物,以有效地抑制DPP-IV的活性,从而有效地用于治疗或预防诸如胰岛素依赖性和胰岛素依赖性糖尿病,关节炎,肥胖症,骨质疏松症和受损葡萄糖耐药性的疾病。 具有β-氨基的1,4-二氮杂环庚烷衍生物由式(1)表示,其中R1是基团(1)或基团(2)。 R2是H,C1-6烷基,C3-6环烷基,C1-6卤代烷基,杂芳基,基团(1),基团(2),基团(3),基团(4),基团(5) ,组(6),组(7),组(8)或组(9); R2是H,C1-6烷基,C3-6环烷基,杂芳基,C1-6烷氧基,-OCH2O,-SO2NH3,-OCF3,苯氧基,卤素,-CN,-NO2,-CF3,-CONH2,-COOR2b ,-CH 2 COOR b,-OCHR 2 bCOOR b或-NR b R c; 每个R b和R c独立地是H,C 1-6烷基或C 3-6环烷基,芳基,烷基芳基,芳基磺酰基,芳基羰基,氨基酸衍生物或-CH 2 OCOC(CH 3)3; R 1是C 1-6烷基,三氟甲基,基团(1),基团(2),基团(10),基团(11),基团(12),基团(13),吡嗪基, 或吡咯基; R 6是C 1-6烷基,C 3-6环烷基,基团(1)或基团(2); (14),基团(15),基团(16),基团(17),基团(10),杂芳基,-S-杂芳基, 四氢异喹啉,噻唑烷,哌啶-4-羧酸或四氢嘧啶; A是CH 2,N,O或S; B是H,C 1-6烷基,C 3-6环烷基,苄基,CO 2 R 12,2-吡啶基或芳基; X是O或S; n为1〜3的整数。一种1,4-二氮杂环庚烷衍生物的制备方法,其特征在于:(a)使式(2)表示的氨基酸和式(3)表示的二氮杂环丁烷化合物 )缩合得到由式(4)表示的化合物; 和(b)使式(4)的化合物脱保护,其中BOC是保护基,其它取代基与上述定义相同。 药物组合物包含有效量的1,4-二氮杂环庚烷衍生物或其药学上可接受的盐和药学上可接受的载体。
Abstract:
A novel pyrazole compound is provided to show excellent inhibitory activity on PDE-4 enzyme, thereby being used in order to prevent and treat asthma, chronic obstructive pulmonary disease, arthritis, atopic dermatitis, tumor and degenerative brain diseases. A 1-(3,4-dialkoxybenzyl)-1H-pyrazole compound is represented by the formula(1), wherein each R1 and R2 is independently H, linear or branched C1-7 alkyl, linear or branched C1-7 C1-7 alkyl including halogen, C3-7 cycloalkyl, (C3-7)cycloalkyl(C1-7)alkyl, 3- to 7-membered heterocycloalkyl including O, N or S in a hetero-cycle, 3- to 7-membered heterocycloalkyl(C1-7)alkyl including O, N or S in a hetero-cycle, phenyl, benzyl or allyl, or R1 and R2 may be linked to each other with C1-3 alkylene or C1-3 alkylene including halogen; R3 is H, formyl, halogen, linear or branched C1-10 alkyl, C1-10 alkoxy, C3-7 cycloalkyl, (C1-7)alkoxy(C1-7)alkyl, C1-7 alkyl ketone, (C3-7)cycloalkyl(C1-7)alkyl, (C3-7)cycloalkyl(C1-7)alkoxy, (C1-10)alkylcarboxylic acid, carboxyl(C1-10)alkylester, carboxyl(C1-10)alkylamide, amino, mono or di(C1-7)alkylamino, mono or di(C1-7)alkylaminocarbonyl; (C3-7)cycloalkylamino, morpholine, morpholine oxide, piperidine, piperazine, piperazine oxide, cyano, nitro, carboxylic acid guanidine, urea, phenoxy, benzyloxy, or an Aryl represented by the group(I); each R4 and R5 is independently H, halogen, formyl, linear or branched C1-10 alkyl, C1-10 alkoxy, (C1-10)alkoxy(C1-10)alkyl, C1-7 alkylketone, hydroxy(C1-10)alkyl, C3-7 cycloalkyl, (C3-7)cycloalkyl(C1-7)alkyl, (C3-7)cycloalkyl(C1-7)alkoxy, carboxylic acid, carboxyl(C1-10)alkylester, carboxyl(C1-10)alkylamide, amino, mono or di(C1-7)alkylamino, mono or di(C1-7)alkylaminocarbonyl, phenyl, phenoxy, benzyl, benzyloxy, 3- to 7-membered heterocycloalkyl including O, N or S in a hetero-cycle, 3- to 7-membered heterocycloalkyl(C1-7)alkyl including O, N or S in a hetero-cycle, 3- to 7-membered heterocycloalkyl(C1-7)alkoxy including O, N or S in a hetero-cycle, cyano, nitro, (C3-7)cycloalkylamino, guanidine, or urea. A method for preparing the compound of the formula(1) comprises a step of reacting a halobenzyl compound represented by the formula(3) with a pyrazole compound represented by the formula(4), each R1, R2, R3, R4, and R5 are same as defined above, and X is halogen. A pharmaceutical composition for preventing and treating inflammation related diseases such as asthma and chronic obstructive pulmonary diseases comprises the compound of the formula(1) as an effective ingredient.
Abstract:
본 발명은 화학식 1로 표시되는 신규한 2-아릴-7-(3′,4′-디알콕시페닐)-피라졸로[1,5-а]피리미딘 화합물 또는 그의 약제학적으로 허용 가능한 염, 이의 제조 방법 및 이를 유효성분으로 함유하는 것을 특징으로 하는 천식 및 만성폐쇄성 폐질환(Chronic Obstructive Pulmonary Disease)을 포함한 염증관련 질환의 치료를 위한 약제학적 조성물에 관한 것이다. [화학식1]
Abstract:
PURPOSE: A sulfamie derivative is provided to have excellent restraining activity to 11B-hydroxysteroid dehydrogenase type 1 and to be useful for preventing and treating various diseases mediated by 11B-HSD1. CONSTITUTION: A sulfamie derivative and pharmaceutically acceptable salts thereof are represented by chemical formula 1. In chemical formula 1, R^1 is H, C1-6 alkyl, cyano C1-6 alkyl, C3-8 cycloalkyl, substituted or unsubstituted benzyl, phenylethyl, C1-6 alkoxycarbonyl, phenylacetyl, naphthyl, or aryl of substituted 5-10 membered ring, R^2 and R^3 is respectively C1-6 alkyl or C2-6 alkenyl or R^2 and R^3 forms a ring, R^4 and R^5 is respectively H or C1-C^ alkyl, R^6 is H, OH, COOR^7 or CONR^7R^7, R^7 is H or C1-6 alkyl, and n is an integer from 1-3.
Abstract translation:目的:提供一种磺胺衍生物,对1型11B-羟类固醇脱氢酶具有优异的抑制活性,可用于预防和治疗11B-HSD1介导的各种疾病。 组成:氨基磺酸衍生物及其药学上可接受的盐由化学式1表示。在化学式1中,R 1是H,C 1-6烷基,氰基C 1-6烷基,C 3-8环烷基,取代或未取代的苄基,苯乙基 C 1-6烷氧基羰基,苯乙酰基,萘基或被取代的5-10元环的芳基,R 2和R 3分别是C 1-6烷基或C 2-6烯基,或者R 2和R 3形成环, R 4和R 5分别是H或C 1 -C 12烷基,R 6是H,OH,COOR 7或CONR 7 R 17,R 7是H或C 1-6烷基,n是 1-3的整数。
Abstract:
본 발명은 인덴온 유도체 및 이의 생리학적으로 허용가능한 염을 유효성분으로 포함하는 골 질환의 예방 또는 치료용 약학적 조성물에 관한 것으로서, 본 발명에 따른 조성물은 조골세포의 활성을 증진시키는 동시에 파골세포의 골 흡수를 억제하는 효과가 우수하여 골다공증을 포함하는 골 질환의 치료에 유용하다. 인덴온 유도체, 골 질환, 약학 조성물